Try Alerts Free   |   Login
Health Care › Surgical And Medical Instruments And Apparatus

SRDX Price Correlated With Financials For Surmodics

Free historical financial statements for Surmodics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 44 quarters since 2011. Compare with SRDX stock chart to see long term trends.

SRDX Stock Compared to Quarterly

SRDX Income Statement

Revenue, Net:25988000
Revenue Per Share:1.851
Cost of Goods & Services Sold:5597000
Selling, General & Admin Expense:13776000
Research & Development Expense:12259000
Total Operating Expenses:32601000
Operating Income:-6792000
Income Taxes:7936000
Net Income:-14728000
Earnings Per Share, Basic:-1.06
Shares Outstanding, Basic Avg:14040000

SRDX Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:2240000
Net Cash from Operations:-2500000
Net Cash from Operations Per Share:-0.1781
Net Cash from Financing Activities:298000
Property, Plant & Equipment Purchases:572000
Net Cash from Investing Activities:1428000
Net Change in Cash & Equivalents:-1076000

SRDX Balance Sheet

Cash and Cash Equivalents:18998000
Accounts Receivable, Net:10452000
Inventories:11819000
Total Current Assets:57587000
Property, Plant & Equipment, Net:27148000
Total Assets:158359000
Accounts Payable:3136000
Total Short-Term Liabilities:32079000
Total Liabilities:49967000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
2,269,299 sh
-18,581 sh
-1%
$68,985
-$16,194
Trigran Investments, Inc.
2,268,162 sh
59,614 sh
3%
$68,953
-$13,271
Vanguard Group Inc
974,726 sh
15,867 sh
2%
$29,632
-$6,066
Soleus Capital Management, L.P.
768,478 sh
107,474 sh
16%
$23,362
-$1,247
Renaissance Technologies LLC
640,238 sh
-45,262 sh
-7%
$19,463
-$11,611
Wellington Management Group Llp
571,178 sh
-21,092 sh
-4%
$17,364
-$4,687
State Street Corp
508,352 sh
5,296 sh
1%
$15,454
-$3,275
Dimensional Fund Advisors LP
450,467 sh
-7,151 sh
-2%
$13,695
-$3,342
Disciplined Growth Investors Inc /Mn
407,872 sh
333 sh
0%
$12,399
-$2,774
Royce & Associates Lp
381,313 sh
401 sh
0%
$11,592
-$2,589
Janus Henderson Group Plc
371,954 sh
-36,119 sh
-9%
$11,308
-$3,884
Segall Bryant & Hamill, LLC
295,144 sh
8,505 sh
3%
$8,971
-$1,696
Geode Capital Management, LLC
247,225 sh
3,190 sh
1%
$7,515
-$1,570
Millennium Management LLC
235,802 sh
43,629 sh
23%
$7,168
$13
Acadian Asset Management LLC
234,964 sh
-8,256 sh
-3%
$7,141
-$1,916
Northern Trust Corp
160,882 sh
-3,003 sh
-2%
$4,891
-$2,538
Bank Of New York Mellon Corp
125,801 sh
1,850 sh
1%
$3,824
-$790
Charles Schwab Investment Management Inc
101,877 sh
2,266 sh
2%
$3,098
-$611
Goldman Sachs Group Inc
98,639 sh
-9,385 sh
-9%
$2,999
-$1,022
Ameriprise Financial Inc
96,738 sh
-619 sh
-1%
$2,940
-$684
COMPANY PROFILE
1. Basis of Presentation
Overview
Surmodics, Inc. and subsidiaries (“Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2021, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC.
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three and nine months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the entire 2022 fiscal year.
Certain reclassifications have been made to the prior year's consolidated financial statements to conform to the current year presentation.
New Accounting Pronouncements
No new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Data imported from Surmodics Inc SEC filings. Check original filings before making any investment decision.